Lucent Diagnostics, a division of Quanterix Corporation, has entered into a partnership with Life Line Screening to expand access to advanced blood-based diagnostic tests across the United States. Announced on **March 2, 2026**, this collaboration aims to provide non-invasive biomarker testing to communities, beginning with programs already active in **Florida**, **California**, and **Texas**.
The partnership aligns with both organizations’ missions to enhance public health through accessible testing. According to the **Alzheimer’s Association**, approximately **7 million Americans** currently live with Alzheimer’s disease, while an additional **6 to 7 million** exhibit symptoms of Mild Cognitive Impairment (MCI). These statistics emphasize the pressing need for scalable testing solutions that enable early detection and intervention.
“Too many chronic conditions go undetected until they become life-altering events,” stated **Jim Waters**, Chief Operating Officer of Life Line Screening. He highlighted the potential impact of this partnership, noting that it could facilitate more informed treatment pathways for individuals at risk.
Life Line Screening, a national organization dedicated to identifying asymptomatic risks for chronic conditions, will leverage its mobile delivery model to provide blood testing in accessible venues such as community centers, churches, and senior centers. This approach not only brings cutting-edge medical technology to the public but also ensures that test results can be shared with primary care physicians for early intervention.
“Scientific rigor shouldn’t stop at the laboratory door,” said **Zachary Fernandes**, General Manager of Lucent Diagnostics. He emphasized that this collaboration makes validated, high-quality scientific testing available outside traditional research settings, which is crucial for reliable early detection of Alzheimer’s disease.
Life Line Screening operates in **48 states**, conducting over **15,000 community events** annually. Their extensive reach allows them to serve both densely populated urban areas and underserved rural regions, delivering preventive health screenings to a wide audience.
For more information about Life Line Screening, visit www.lifelinescreening.com. To learn more about Lucent Diagnostics and its parent company, Quanterix Corporation, visit www.lucentdiagnostics.com.
This partnership represents a significant step towards addressing the public health challenges associated with cognitive diseases. By making advanced diagnostic tools more accessible, Lucent Diagnostics and Life Line Screening aim to empower individuals to take charge of their health and facilitate timely medical interventions.
